Migraine treatment and COVID-19 vaccines: No cause for concern.
作者信息
Gelfand Amy A, Poland Gregory
机构信息
Child & Adolescent Headache Program, University of California, San Francisco, San Francisco, CA, USA.
Mayo Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
出版信息
Headache. 2021 Mar;61(3):409-411. doi: 10.1111/head.14086.
Abstract
摘要
相似文献
1
Migraine treatment and COVID-19 vaccines: No cause for concern.
Headache. 2021 Mar;61(3):409-411. doi: 10.1111/head.14086.
2
COVID-19 vaccines for patients with haematological conditions.
Lancet Haematol. 2021 May;8(5):e312-e314. doi: 10.1016/S2352-3026(21)00073-9. Epub 2021 Mar 31.
3
The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):89-91. doi: 10.18176/jiaci.0665. Epub 2020 Jan 4.
4
Talk of the town in 2021: Covid-19 vaccines likely take centre stage.
Scand J Immunol. 2021 Jan;93(1):e13014. doi: 10.1111/sji.13014.
5
Equitable global access to coronavirus disease 2019 vaccines.
BMJ. 2020 Dec 15;371:m4735. doi: 10.1136/bmj.m4735.
6
Cancer and COVID-19 vaccines: a complex global picture.
Lancet Oncol. 2021 Jun;22(6):749-751. doi: 10.1016/S1470-2045(21)00244-8. Epub 2021 Apr 27.
7
COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic.
Anaesthesia. 2021 Apr;76(4):435-443. doi: 10.1111/anae.15365. Epub 2020 Dec 14.
8
SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.
Ann Rheum Dis. 2021 Oct;80(10):1249-1251. doi: 10.1136/annrheumdis-2021-221251.
9
COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.
Neurosciences (Riyadh). 2021 Apr;26(2):222-223.
10
A Reserve System for the Equitable Allocation of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
Chest. 2021 Mar;159(3):1292-1293. doi: 10.1016/j.chest.2020.08.2042. Epub 2021 Jan 14.
引用本文的文献
1
Central nervous system manifestations following vaccination against COVID-19.
Brain Behav Immun Health. 2024 May 3;38:100788. doi: 10.1016/j.bbih.2024.100788. eCollection 2024 Jul.
2
An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations.
Int Immunopharmacol. 2023 Apr;117:109934. doi: 10.1016/j.intimp.2023.109934. Epub 2023 Feb 27.
3
Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting.
Curr Pain Headache Rep. 2022 Dec;26(12):895-918. doi: 10.1007/s11916-022-01094-y. Epub 2022 Nov 23.
4
Navigating migraine care through the COVID-19 pandemic: an update.
J Neurol. 2021 Nov;268(11):4388-4395. doi: 10.1007/s00415-021-10610-w. Epub 2021 May 17.
本文引用的文献
1
Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.
J Virol. 2021 Mar 10;95(7). doi: 10.1128/JVI.00014-21. Epub 2021 Jan 13.
2
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
BMC Neurol. 2020 Feb 15;20(1):57. doi: 10.1186/s12883-020-01633-3.
3
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.
Brain Behav. 2019 Feb;9(2):e01215. doi: 10.1002/brb3.1215. Epub 2019 Jan 18.
4
Effect of antipyretic analgesics on immune responses to vaccination.
Hum Vaccin Immunother. 2016 Sep;12(9):2391-402. doi: 10.1080/21645515.2016.1183077. Epub 2016 May 31.
5
Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis.
Front Neurosci. 2014 Feb 14;8:23. doi: 10.3389/fnins.2014.00023. eCollection 2014.
6
Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities.
Eur J Immunol. 1999 Aug;29(8):2613-24. doi: 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J.
Zotero 插件